Elucidating a

Lee Moffitt Cancer Center), Felix Feng, MD (University of California, San Francisco) Co-Investigators: Jonathan Chou, MD (University of California, San Francisco), Kiran Mahajan, Ph D (H.Lee Moffitt Cancer Center), Rajdeep Das, MBBS, Ph D (University of California, San Francisco), Eric Small, MD (University of California, San Francisco), Amrita Basu, Ph D (H.This team will test whether an intense, multimodal treatment strategy can be curative in these patients, and establish biomarkers for identifying the patients who should receive this treatment.2017 PCF Challenge Award (

Lee Moffitt Cancer Center), Felix Feng, MD (University of California, San Francisco) Co-Investigators: Jonathan Chou, MD (University of California, San Francisco), Kiran Mahajan, Ph D (H.Lee Moffitt Cancer Center), Rajdeep Das, MBBS, Ph D (University of California, San Francisco), Eric Small, MD (University of California, San Francisco), Amrita Basu, Ph D (H.This team will test whether an intense, multimodal treatment strategy can be curative in these patients, and establish biomarkers for identifying the patients who should receive this treatment.2017 PCF Challenge Award ($1 Million) Award Donor: Stein Erik Hagen Principal Investigators: Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian), Neil Bander, MD (Weill Cornell Medicine and New York-Presbyterian), Shankar Vallabhajosula, Ph D (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: John Babich, Ph D (Weill Cornell Medicine and New York-Presbyterian), Karla Ballman, Ph D (Weill Cornell Medicine and New York-Presbyterian), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian), Yuliya Jhanwar, MD (Weill Cornell Medicine and New York-Presbyterian), Oliver Sartor, MD (Tulane University), Lauren Harshman, MD (Harvard: Dana-Farber Cancer Institute), Johannes Czernin, MD (University of California, Los Angeles), Sacha Gnjatic, MD (Icahn School of Medicine at Mount Sinai Hospital), Francesca Khani, MD (Weill Cornell Medicine and New York-Presbyterian) Project Title: Optimization of Prostate-Specific Membrane Antigen-Targeted Radiation Description: What this means to patients: Recent studies have suggested that PSMA-targeted radiation therapy may be highly effective in men with advanced prostate cancer, however controlled clinical trials have not yet been conducted for these agents.Lee Moffitt Cancer Center) Project Title: Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer.

||

Lee Moffitt Cancer Center), Felix Feng, MD (University of California, San Francisco) Co-Investigators: Jonathan Chou, MD (University of California, San Francisco), Kiran Mahajan, Ph D (H.

Lee Moffitt Cancer Center), Rajdeep Das, MBBS, Ph D (University of California, San Francisco), Eric Small, MD (University of California, San Francisco), Amrita Basu, Ph D (H.

This team will test whether an intense, multimodal treatment strategy can be curative in these patients, and establish biomarkers for identifying the patients who should receive this treatment.

Million) Award Donor: Stein Erik Hagen Principal Investigators: Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian), Neil Bander, MD (Weill Cornell Medicine and New York-Presbyterian), Shankar Vallabhajosula, Ph D (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: John Babich, Ph D (Weill Cornell Medicine and New York-Presbyterian), Karla Ballman, Ph D (Weill Cornell Medicine and New York-Presbyterian), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian), Yuliya Jhanwar, MD (Weill Cornell Medicine and New York-Presbyterian), Oliver Sartor, MD (Tulane University), Lauren Harshman, MD (Harvard: Dana-Farber Cancer Institute), Johannes Czernin, MD (University of California, Los Angeles), Sacha Gnjatic, MD (Icahn School of Medicine at Mount Sinai Hospital), Francesca Khani, MD (Weill Cornell Medicine and New York-Presbyterian) Project Title: Optimization of Prostate-Specific Membrane Antigen-Targeted Radiation Description: What this means to patients: Recent studies have suggested that PSMA-targeted radiation therapy may be highly effective in men with advanced prostate cancer, however controlled clinical trials have not yet been conducted for these agents.Lee Moffitt Cancer Center) Project Title: Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer.

2017 Movember Foundation – PCF Challenge Award (

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Ana Aparicio, MD (The University of Texas MD Anderson Cancer Center), Nicholas Navin, Ph D (The University of Texas MD Anderson Cancer Center), Theocharis Panaretakis, Ph D (The University of Texas MD Anderson Cancer Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Brian Chapin, MD (The University of Texas MD Anderson Cancer Center), James Hicks, Ph D (University of Southern California), Patricia Troncoso, MD (The University of Texas MD Anderson Cancer Center) Project Title: Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets Description: What this means to patients: Some men who have metastatic prostate cancer at the time of diagnosis may benefit from treatment of the primary tumor in addition to standard systemic therapy. Aparicio and team will develop biomarkers that can be used to identify which of these patients will benefit from treatment of the primary prostate tumor.

2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Ressler, Emanuel J.

Friedman Philanthropies, James Cox Foundation Principal Investigators: Maha Hussain, MD (Northwestern University), Edward Schaeffer, MD, Ph D (Northwestern University), Joshua Meeks, MD, Ph D (Northwestern University; Jesse Brown VA Medical Center) Co-Investigators: Sarki Abba Abdulkadir, MD, Ph D (Northwestern University), Benedito Carneiro, MD (Northwestern University), Alicia Morgans, MD, MPH (Northwestern University), Barko Jovanovic, Ph D (Northwestern University), Ami Shah, MD (Northwestern University), Scott Tomlins MD, Ph D (University of Michigan), Philip Palmbos, MD, Ph D (University of Michigan), Roohollah Sharifi, MD (Jesse Brown VA Medical Center) Project Title: Clinical, Environmental, Genetic and Genomic profile of Men with Early-Onset Lethal Prostate Cancer Description: What this means to patients: Prostate cancers can appear clinically and pathologically similar yet have distinct natural histories and responses to therapy.

||

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Ana Aparicio, MD (The University of Texas MD Anderson Cancer Center), Nicholas Navin, Ph D (The University of Texas MD Anderson Cancer Center), Theocharis Panaretakis, Ph D (The University of Texas MD Anderson Cancer Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Brian Chapin, MD (The University of Texas MD Anderson Cancer Center), James Hicks, Ph D (University of Southern California), Patricia Troncoso, MD (The University of Texas MD Anderson Cancer Center) Project Title: Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets Description: What this means to patients: Some men who have metastatic prostate cancer at the time of diagnosis may benefit from treatment of the primary tumor in addition to standard systemic therapy. Aparicio and team will develop biomarkers that can be used to identify which of these patients will benefit from treatment of the primary prostate tumor.2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Ressler, Emanuel J.Friedman Philanthropies, James Cox Foundation Principal Investigators: Maha Hussain, MD (Northwestern University), Edward Schaeffer, MD, Ph D (Northwestern University), Joshua Meeks, MD, Ph D (Northwestern University; Jesse Brown VA Medical Center) Co-Investigators: Sarki Abba Abdulkadir, MD, Ph D (Northwestern University), Benedito Carneiro, MD (Northwestern University), Alicia Morgans, MD, MPH (Northwestern University), Barko Jovanovic, Ph D (Northwestern University), Ami Shah, MD (Northwestern University), Scott Tomlins MD, Ph D (University of Michigan), Philip Palmbos, MD, Ph D (University of Michigan), Roohollah Sharifi, MD (Jesse Brown VA Medical Center) Project Title: Clinical, Environmental, Genetic and Genomic profile of Men with Early-Onset Lethal Prostate Cancer Description: What this means to patients: Prostate cancers can appear clinically and pathologically similar yet have distinct natural histories and responses to therapy.

Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award (

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Ana Aparicio, MD (The University of Texas MD Anderson Cancer Center), Nicholas Navin, Ph D (The University of Texas MD Anderson Cancer Center), Theocharis Panaretakis, Ph D (The University of Texas MD Anderson Cancer Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Brian Chapin, MD (The University of Texas MD Anderson Cancer Center), James Hicks, Ph D (University of Southern California), Patricia Troncoso, MD (The University of Texas MD Anderson Cancer Center) Project Title: Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets Description: What this means to patients: Some men who have metastatic prostate cancer at the time of diagnosis may benefit from treatment of the primary tumor in addition to standard systemic therapy. Aparicio and team will develop biomarkers that can be used to identify which of these patients will benefit from treatment of the primary prostate tumor.

2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Ressler, Emanuel J.

Friedman Philanthropies, James Cox Foundation Principal Investigators: Maha Hussain, MD (Northwestern University), Edward Schaeffer, MD, Ph D (Northwestern University), Joshua Meeks, MD, Ph D (Northwestern University; Jesse Brown VA Medical Center) Co-Investigators: Sarki Abba Abdulkadir, MD, Ph D (Northwestern University), Benedito Carneiro, MD (Northwestern University), Alicia Morgans, MD, MPH (Northwestern University), Barko Jovanovic, Ph D (Northwestern University), Ami Shah, MD (Northwestern University), Scott Tomlins MD, Ph D (University of Michigan), Philip Palmbos, MD, Ph D (University of Michigan), Roohollah Sharifi, MD (Jesse Brown VA Medical Center) Project Title: Clinical, Environmental, Genetic and Genomic profile of Men with Early-Onset Lethal Prostate Cancer Description: What this means to patients: Prostate cancers can appear clinically and pathologically similar yet have distinct natural histories and responses to therapy.

||

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Ana Aparicio, MD (The University of Texas MD Anderson Cancer Center), Nicholas Navin, Ph D (The University of Texas MD Anderson Cancer Center), Theocharis Panaretakis, Ph D (The University of Texas MD Anderson Cancer Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Brian Chapin, MD (The University of Texas MD Anderson Cancer Center), James Hicks, Ph D (University of Southern California), Patricia Troncoso, MD (The University of Texas MD Anderson Cancer Center) Project Title: Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets Description: What this means to patients: Some men who have metastatic prostate cancer at the time of diagnosis may benefit from treatment of the primary tumor in addition to standard systemic therapy. Aparicio and team will develop biomarkers that can be used to identify which of these patients will benefit from treatment of the primary prostate tumor.2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Ressler, Emanuel J.Friedman Philanthropies, James Cox Foundation Principal Investigators: Maha Hussain, MD (Northwestern University), Edward Schaeffer, MD, Ph D (Northwestern University), Joshua Meeks, MD, Ph D (Northwestern University; Jesse Brown VA Medical Center) Co-Investigators: Sarki Abba Abdulkadir, MD, Ph D (Northwestern University), Benedito Carneiro, MD (Northwestern University), Alicia Morgans, MD, MPH (Northwestern University), Barko Jovanovic, Ph D (Northwestern University), Ami Shah, MD (Northwestern University), Scott Tomlins MD, Ph D (University of Michigan), Philip Palmbos, MD, Ph D (University of Michigan), Roohollah Sharifi, MD (Jesse Brown VA Medical Center) Project Title: Clinical, Environmental, Genetic and Genomic profile of Men with Early-Onset Lethal Prostate Cancer Description: What this means to patients: Prostate cancers can appear clinically and pathologically similar yet have distinct natural histories and responses to therapy.

Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.2017 Movember Foundation – PCF Challenge Award (

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Ana Aparicio, MD (The University of Texas MD Anderson Cancer Center), Nicholas Navin, Ph D (The University of Texas MD Anderson Cancer Center), Theocharis Panaretakis, Ph D (The University of Texas MD Anderson Cancer Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Brian Chapin, MD (The University of Texas MD Anderson Cancer Center), James Hicks, Ph D (University of Southern California), Patricia Troncoso, MD (The University of Texas MD Anderson Cancer Center) Project Title: Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets Description: What this means to patients: Some men who have metastatic prostate cancer at the time of diagnosis may benefit from treatment of the primary tumor in addition to standard systemic therapy. Aparicio and team will develop biomarkers that can be used to identify which of these patients will benefit from treatment of the primary prostate tumor.

2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Ressler, Emanuel J.

Friedman Philanthropies, James Cox Foundation Principal Investigators: Maha Hussain, MD (Northwestern University), Edward Schaeffer, MD, Ph D (Northwestern University), Joshua Meeks, MD, Ph D (Northwestern University; Jesse Brown VA Medical Center) Co-Investigators: Sarki Abba Abdulkadir, MD, Ph D (Northwestern University), Benedito Carneiro, MD (Northwestern University), Alicia Morgans, MD, MPH (Northwestern University), Barko Jovanovic, Ph D (Northwestern University), Ami Shah, MD (Northwestern University), Scott Tomlins MD, Ph D (University of Michigan), Philip Palmbos, MD, Ph D (University of Michigan), Roohollah Sharifi, MD (Jesse Brown VA Medical Center) Project Title: Clinical, Environmental, Genetic and Genomic profile of Men with Early-Onset Lethal Prostate Cancer Description: What this means to patients: Prostate cancers can appear clinically and pathologically similar yet have distinct natural histories and responses to therapy.

||

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Ana Aparicio, MD (The University of Texas MD Anderson Cancer Center), Nicholas Navin, Ph D (The University of Texas MD Anderson Cancer Center), Theocharis Panaretakis, Ph D (The University of Texas MD Anderson Cancer Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Brian Chapin, MD (The University of Texas MD Anderson Cancer Center), James Hicks, Ph D (University of Southern California), Patricia Troncoso, MD (The University of Texas MD Anderson Cancer Center) Project Title: Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets Description: What this means to patients: Some men who have metastatic prostate cancer at the time of diagnosis may benefit from treatment of the primary tumor in addition to standard systemic therapy. Aparicio and team will develop biomarkers that can be used to identify which of these patients will benefit from treatment of the primary prostate tumor.2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Ressler, Emanuel J.Friedman Philanthropies, James Cox Foundation Principal Investigators: Maha Hussain, MD (Northwestern University), Edward Schaeffer, MD, Ph D (Northwestern University), Joshua Meeks, MD, Ph D (Northwestern University; Jesse Brown VA Medical Center) Co-Investigators: Sarki Abba Abdulkadir, MD, Ph D (Northwestern University), Benedito Carneiro, MD (Northwestern University), Alicia Morgans, MD, MPH (Northwestern University), Barko Jovanovic, Ph D (Northwestern University), Ami Shah, MD (Northwestern University), Scott Tomlins MD, Ph D (University of Michigan), Philip Palmbos, MD, Ph D (University of Michigan), Roohollah Sharifi, MD (Jesse Brown VA Medical Center) Project Title: Clinical, Environmental, Genetic and Genomic profile of Men with Early-Onset Lethal Prostate Cancer Description: What this means to patients: Prostate cancers can appear clinically and pathologically similar yet have distinct natural histories and responses to therapy.

Million) Principal Investigators: Ana Aparicio, MD (The University of Texas MD Anderson Cancer Center), Nicholas Navin, Ph D (The University of Texas MD Anderson Cancer Center), Theocharis Panaretakis, Ph D (The University of Texas MD Anderson Cancer Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Brian Chapin, MD (The University of Texas MD Anderson Cancer Center), James Hicks, Ph D (University of Southern California), Patricia Troncoso, MD (The University of Texas MD Anderson Cancer Center) Project Title: Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets Description: What this means to patients: Some men who have metastatic prostate cancer at the time of diagnosis may benefit from treatment of the primary tumor in addition to standard systemic therapy. Aparicio and team will develop biomarkers that can be used to identify which of these patients will benefit from treatment of the primary prostate tumor.2017 PCF VALOR Challenge Award (

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Ana Aparicio, MD (The University of Texas MD Anderson Cancer Center), Nicholas Navin, Ph D (The University of Texas MD Anderson Cancer Center), Theocharis Panaretakis, Ph D (The University of Texas MD Anderson Cancer Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Brian Chapin, MD (The University of Texas MD Anderson Cancer Center), James Hicks, Ph D (University of Southern California), Patricia Troncoso, MD (The University of Texas MD Anderson Cancer Center) Project Title: Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets Description: What this means to patients: Some men who have metastatic prostate cancer at the time of diagnosis may benefit from treatment of the primary tumor in addition to standard systemic therapy. Aparicio and team will develop biomarkers that can be used to identify which of these patients will benefit from treatment of the primary prostate tumor.

2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Ressler, Emanuel J.

Friedman Philanthropies, James Cox Foundation Principal Investigators: Maha Hussain, MD (Northwestern University), Edward Schaeffer, MD, Ph D (Northwestern University), Joshua Meeks, MD, Ph D (Northwestern University; Jesse Brown VA Medical Center) Co-Investigators: Sarki Abba Abdulkadir, MD, Ph D (Northwestern University), Benedito Carneiro, MD (Northwestern University), Alicia Morgans, MD, MPH (Northwestern University), Barko Jovanovic, Ph D (Northwestern University), Ami Shah, MD (Northwestern University), Scott Tomlins MD, Ph D (University of Michigan), Philip Palmbos, MD, Ph D (University of Michigan), Roohollah Sharifi, MD (Jesse Brown VA Medical Center) Project Title: Clinical, Environmental, Genetic and Genomic profile of Men with Early-Onset Lethal Prostate Cancer Description: What this means to patients: Prostate cancers can appear clinically and pathologically similar yet have distinct natural histories and responses to therapy.

||

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Ana Aparicio, MD (The University of Texas MD Anderson Cancer Center), Nicholas Navin, Ph D (The University of Texas MD Anderson Cancer Center), Theocharis Panaretakis, Ph D (The University of Texas MD Anderson Cancer Center), Peter Kuhn, Ph D (University of Southern California) Co-Investigators: Brian Chapin, MD (The University of Texas MD Anderson Cancer Center), James Hicks, Ph D (University of Southern California), Patricia Troncoso, MD (The University of Texas MD Anderson Cancer Center) Project Title: Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets Description: What this means to patients: Some men who have metastatic prostate cancer at the time of diagnosis may benefit from treatment of the primary tumor in addition to standard systemic therapy. Aparicio and team will develop biomarkers that can be used to identify which of these patients will benefit from treatment of the primary prostate tumor.2017 PCF VALOR Challenge Award ($1 Million) Award Donors: Richard Ressler, Emanuel J.Friedman Philanthropies, James Cox Foundation Principal Investigators: Maha Hussain, MD (Northwestern University), Edward Schaeffer, MD, Ph D (Northwestern University), Joshua Meeks, MD, Ph D (Northwestern University; Jesse Brown VA Medical Center) Co-Investigators: Sarki Abba Abdulkadir, MD, Ph D (Northwestern University), Benedito Carneiro, MD (Northwestern University), Alicia Morgans, MD, MPH (Northwestern University), Barko Jovanovic, Ph D (Northwestern University), Ami Shah, MD (Northwestern University), Scott Tomlins MD, Ph D (University of Michigan), Philip Palmbos, MD, Ph D (University of Michigan), Roohollah Sharifi, MD (Jesse Brown VA Medical Center) Project Title: Clinical, Environmental, Genetic and Genomic profile of Men with Early-Onset Lethal Prostate Cancer Description: What this means to patients: Prostate cancers can appear clinically and pathologically similar yet have distinct natural histories and responses to therapy.

Million) Award Donors: Richard Ressler, Emanuel J.Friedman Philanthropies, James Cox Foundation Principal Investigators: Maha Hussain, MD (Northwestern University), Edward Schaeffer, MD, Ph D (Northwestern University), Joshua Meeks, MD, Ph D (Northwestern University; Jesse Brown VA Medical Center) Co-Investigators: Sarki Abba Abdulkadir, MD, Ph D (Northwestern University), Benedito Carneiro, MD (Northwestern University), Alicia Morgans, MD, MPH (Northwestern University), Barko Jovanovic, Ph D (Northwestern University), Ami Shah, MD (Northwestern University), Scott Tomlins MD, Ph D (University of Michigan), Philip Palmbos, MD, Ph D (University of Michigan), Roohollah Sharifi, MD (Jesse Brown VA Medical Center) Project Title: Clinical, Environmental, Genetic and Genomic profile of Men with Early-Onset Lethal Prostate Cancer Description: What this means to patients: Prostate cancers can appear clinically and pathologically similar yet have distinct natural histories and responses to therapy.

Leave a Reply